- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01937013
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia (IEMO)
August 7, 2018 updated by: Elizabeth Finger, Lawson Health Research Institute
This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Frontotemporal dementia (FTD) and Pick's disease cause changes in personality, behaviour, and emotional responses.
The usual treatments for Frontotemporal dementia focus on reducing agitation and aggressive behaviours.
However, these drugs do not help all patients who experience blunting of emotion and loss of empathy.
This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6C 5J1
- Parkwood Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients:
- Ages 30-85
- meet consensus criteria for probable behavioural variant FTD (bvFTD)
Controls:
- Age and sex matched with patients
- Mini-Mental State Exam (MMSE) scores >27
Exclusion Criteria:
Patients:
- history of stroke
- intracranial haemorrhage or other medical or neurological disorder apart from FTD that could affect cognition
- diagnosis of bipolar disorder or schizophrenia not better accounted for by the diagnosis of FTD
- cognitive impairment that precludes comprehension of task instructions
- contraindication to MRI scanning
- severe language or memory deficits that preclude participation in the study visits and measures
- females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).
- uncontrolled hypertension
- bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)
- current use of prostaglandins
Controls:
- history of stroke
- intracranial haemorrhage or other medical or neurological disorder
- diagnosis of bipolar disorder or schizophrenia
- cognitive impairment that precludes comprehension of task instructions
- contraindication to MRI scanning
- severe language or memory deficits that preclude participation in the study visits and measures
- females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause).
- uncontrolled hypertension
- bradycardia (rate <48 bpm) or tachycardia (rate > 100 bpm)
- current use of prostaglandins
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intranasal Oxytocin
Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
|
Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose).
The intravenous form of drug is approved by Health Canada for use in pregnancy.
The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding).
Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
Other Names:
|
Placebo Comparator: Saline Nasal Mist
Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
|
Participants will be randomized to receive placebo on either study visit 2 or 3.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional magnetic resonance imaging (fMRI) BOLD signal
Time Frame: 2 weeks
|
Measures of BOLD (Blood Oxygen-Level Dependent) signal change during oxytocin compared to placebo during functional MRI scans
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive and Emotional Task performance
Time Frame: 2 weeks
|
Performance on standardized tasks of emotion processing and cognition
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth C Finger, M.D., LawsonHRI, London Health Sciences Centre, Western University, Schulich School of Medicine
- Principal Investigator: Derek Mitchell, PhD, Western University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2013
Primary Completion (Actual)
December 21, 2017
Study Completion (Actual)
December 21, 2017
Study Registration Dates
First Submitted
September 3, 2013
First Submitted That Met QC Criteria
September 3, 2013
First Posted (Estimate)
September 9, 2013
Study Record Updates
Last Update Posted (Actual)
August 8, 2018
Last Update Submitted That Met QC Criteria
August 7, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
- Physiological Effects of Drugs
- Reproductive Control Agents
- Oxytocics
- Oxytocin
Other Study ID Numbers
- R-13-270
- 166786 (Other Identifier: Health Canada)
- 103555 (Other Identifier: Western HSREB)
- FTDOXY13EF (Other Identifier: Internal)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Dementia
-
University of California, San FranciscoForest LaboratoriesCompletedSemantic Dementia | Frontal Lobe Dementia | Frontotemporal Lobe DementiaUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Behavioral Variant of Frontotemporal Dementia | Frontotemporal Dementia, Behavioral VariantUnited States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Caregiver Stress Syndrome | Caregiver Burnout | Dementia, Mild | Dementia Moderate | Dementia Severe | Dementia FrontotemporalUnited States
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
Vesper Biotechnologies ApSRecruitingDementia, FrontotemporalNetherlands
-
HealthPartners InstituteTerminatedFrontotemporal Dementia, Behavioral VariantUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...CompletedFamilial Frontotemporal DementiaUnited States, Canada
Clinical Trials on Intranasal oxytocin
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
University of Electronic Science and Technology...Completed
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingAutism Spectrum Disorder | Bone HealthUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingBorderline Personality DisorderUnited States
-
MacDonald, Kai, M.D.CompletedAnxiety | BehaviorUnited States
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
University of Electronic Science and Technology...Completed
-
University of Electronic Science and Technology...Completed
-
University of Electronic Science and Technology...Unknown
-
University of Electronic Science and Technology...Recruiting